Mahdi Karimi received his BSc degree in Medical Laboratory Science from the Iran University of Medical Science (IUMS), in 2005. In 2008, he earned an MSc degree in Medical Biotechnology from Tabriz University of Medical Science and joined the Tarbiat Modares University as a PhD student in the nanobiotechnology field and completed his research in 2013. During his research, in 2012, he worked with the laboratory of Professor Michael Hamblin in the Wellman Center for Photomedicine at Massachusetts General Hospital and Harvard Medical School as a visiting researcher, where he contributed to the design and construction of new smart nanoparticles for drug/gene delivery. He went on to join the Department of Medical Nanotechnology at IUMS as an Assistant Professor. His current research interests include smart nanoparticles' design in drug/gene delivery and microfluidic systems. Maryam Rad Mansouri received her BSc degree in biology from Tabriz University in 2008. In 2013 she received an MSc degree in clinical biochemistry from Isfahan University of Medical Science. After graduation, she continued her studies in the design of therapeutic nanoparticles for drug delivery.
Her current research interests include biomimetic nanoparticle design in drug/gene delivery systems. Navid Rabiee graduated with a BSc degree from Shahid Beheshti University, Tehran, Iran, in 2016. In 2018, he received his MSc in Inorganic Chemistry from Shahid Beheshti University, Tehran, Iran. During his MSc research, he worked on Porphyrin-based Biosensors and the application of Porphyrins and Cobalt Complexes on Dye Sensitized Solar Cells (DSSC) under the supervision of Prof. Nasser Safari. He also focused on Drug Delivery Systems based on biocompatible and biodegradable polymers associated with different types of the sensitizers, especially porphyrins, under the supervision of Prof. Mohammad Rabiee at Amirkabir University of Technology, Tehran, Iran. In 2017, he joined ANNRG to collaborate with Prof.
Mahdi Karimi's Research lab in Iran University of Medical Science, Tehran, Iran, in association with Prof. Michael R. Hamblin from Harvard Medical University, Boston, MA, working on smart microcarriers/nanocarriers applied in therapeutic agent delivery systems employed for diagnosis and therapy of various disease and disorders such as different cancers and malignancies, inflammations, infections, etc. Michael R. Hamblin Ph.D. is a Principal Investigator at Wellman Center for Photomedicine, Massachusetts General Hospital, and an Associate Professor at Harvard Medical School. He has interests in photodynamic therapy and photobiomodulation.
He has published 420 peer-reviewed articles, is Editor-in-Chief of Photobiomodulation, Photomedicine and Laser Surgery, Associate Editor for 10 other journals and serves on NIH Study-Sections. He has an h-factor 91 and >33,000 citations. He has authored/edited 23 textbooks on PDT and photomedicine including SPIE proceedings. Dr Hamblin was elected as a Fellow of SPIE in 2011, received 1st Endre Mester Lifetime Achievement Award Photomedicine from NAALT in 2017, and Outstanding Career Award from Dose Response Society in 2018.